Osteoarthritis (oa) pain therapeutics pipeline assessment and market forecasts to 2019Document Transcript
Osteoarthritis (OA) Pain Therapeutics - Pipeline Assessment and MarketForecasts to 2019GlobalData, the industry analysis specialist, has released its new report, “Osteoarthritis(OA) Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report isan essential source of information and analysis on the global Osteoarthritis PainTherapeutics market. The report identifies the key trends shaping and driving the globalOsteoarthritis Pain Therapeutics market. The report also provides insights on the prevalentcompetitive landscape and the emerging players expected to significantly alter the marketpositioning of the current market leaders. Most importantly, the report provides valuableinsights on the pipeline products within the global Osteoarthritis Pain Therapeutics sector.This report is built using data and information sourced from proprietary databases,primary and secondary research and in-house analysis by GlobalData’s team of industryexperts.ScopeThe report provides information on the key drivers and challenges of the OsteoarthritisPain Therapeutics market. Its scope includes -- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan)Osteoarthritis Pain Therapeutics market revenues data from 2006 to 2011, forecast foreight years to 2019.- Pipeline analysis data providing a split across the different phases, mechanisms of actionbeing developed and emerging trends by seven key markets. Pipeline candidates fall undermajor therapeutic classes.- Analysis of the current and future competition in the seven key countries OsteoarthritisPain Therapeutics market.- Insightful review of the key industry drivers, restraints and challenges. Each trend isindependently researched to provide a qualitative analysis of its implications.- Key topics covered include strategic competitor assessment, market characterization,unmet needs and the implications for the Osteoarthritis Pain Therapeutics market.- Analysis of key recent licensing and partnership agreements in Osteoarthritis PainTherapeutics marketGet more information of this report @ http://www.reportsnreports.com/reports/167923-osteoarthritis-oa-pain-therapeutics-pipeline-assessment-and-market-forecasts-to-2019.htmlReasons to buyThe report will enhance your decision making capability. It will allow you to -- Develop and design your in-licensing and out-licensing strategies through a review of pipeline productsand technologies and by identifying the companies with the most robust pipeline.- Develop business strategies by understanding the trends shaping and driving the global OsteoarthritisPain Therapeutics market.- Drive revenues by understanding the key trends, innovative products and technologies, marketsegments and companies likely to impact the global Osteoarthritis Pain Therapeutics market in future.- Formulate effective sales and marketing strategies by understanding the competitive landscape and byanalyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.- Organize your sales and marketing efforts by identifying the market categories and segments thatpresent maximum opportunities for consolidations, investments and strategic partnerships.- What’s the next big thing in the global Osteoarthritis Pain Therapeutics market landscape? – Identify,understand and capitalize.Report Details:Published: June 2012No. of Pages: 98Price: Single User License: US $ 3995 Corporate User License: US $ 11985Major points covered in Table of Contents of this report include:List of Tables 51.2 List of Figures 62 Osteoarthritis Pain Therapeutics - Introduction 72.1 Disease Overview 72.1.1 Classification of Osteoarthritis 82.1.2 Types of Osteoarthritis 82.1.3 Osteoarthritis Pain 132.2 Epidemiology 132.2.1 Prevalence 132.3 Quality of Life 142.4 Etiology 142.5 Signs and Symptoms 162.6 Diagnosis 162.6.1 Physical Examination 162.6.2 Radiological Examination 172.6.3 Laboratory Test 182.7 Pathophysiology 192.7.1 Progression of the Disease 192.8 Treatment and Management Options 202.8.1 Pharmacological treatment 242.9 Referral Pathway 272.10 GlobalData Pipeline Report Guidance 293 Osteoarthritis Pain Therapeutics - Market Characterization 303.1 Overview 303.2 Osteoarthritis Pain Therapeutics Market Size (2006-2011) – Global 313.3 Osteoarthritis Pain Therapeutics Market Forecast (2011-2019) – Global 32
3.4 Osteoarthritis Pain Therapeutics Market Size (2006-2011) – The US 333.5 Osteoarthritis Pain Therapeutics Market Forecast (2011-2019) – The US 343.6 Osteoarthritis Pain Therapeutics Market Size (2006-2011) – France 353.7 Osteoarthritis Pain Therapeutics Market Forecast (2011-2019) – France 363.8 Osteoarthritis Pain Therapeutics Market Size (2006-2011) – Germany 373.9 Osteoarthritis Pain Therapeutics Market Forecast (2011-2019) – Germany 383.10 Osteoarthritis Pain Therapeutics Market Size (2006-2011) – Italy 393.11 Osteoarthritis Pain Therapeutics Market Forecast (2011-2019) – Italy 403.12 Osteoarthritis Pain Therapeutics Market Size (2006-2011) – Spain 413.13 Osteoarthritis Pain Therapeutics Market Forecast (2011-2019) – Spain 423.14 Osteoarthritis Pain Therapeutics Market Size (2006-2011) – The UK 433.15 Osteoarthritis Pain Therapeutics Market Forecast (2011-2019) – The UK 443.16 Osteoarthritis Pain Therapeutics Market Size (2006-2011) – Japan 453.17 Osteoarthritis Pain Therapeutics Market Forecast (2011-2019) – Japan 463.18 Drivers and Barriers for the Osteoarthritis Pain Therapeutics Market 473.18.1 Drivers for the Osteoarthritis Pain Therapeutics Market 473.18.2 Barriers for the Osteoarthritis Pain Therapeutics Market 483.19 Opportunity and Unmet Need Analysis 493.20 Key Takeaway 504 Osteoarthritis Pain Therapeutics - Competitive Assessment 514.1 Overview 514.2 Strategic Competitor Assessment 514.3 Product Profiles for the Major Marketed Products in the Osteoarthritis Pain Therapeutics Market 534.3.1 Celebrex (celecoxib) 534.3.2 Voltaren Gel (diclofenac sodium) 534.3.3 Hyalgan (sodium hyaluronate) 544.3.4 Cymbalta (duloxetine) 544.3.5 Synvisc (hylan G-F 20) 554.4 Key Takeaway 565 Osteoarthritis Pain Therapeutics - Pipeline Assessment 575.1 Overview 575.2 Strategic Pipeline Assessment 575.3 Osteoarthritis Pain Therapeutics Pipeline – Pipeline by Phases of Development 585.3.1 Osteoarthritis Pain Therapeutics – Regulatory Filed Products 585.3.2 Osteoarthritis Pain Therapeutics – Phase III Pipeline 595.3.3 Osteoarthritis Pain Therapeutics – Phase II/III Pipeline 595.3.4 Osteoarthritis Pain Therapeutics – Phase II Pipeline 605.3.5 Osteoarthritis Pain Therapeutics – Phase I/II Pipeline 605.3.6 Osteoarthritis Pain Therapeutics – Phase I Pipeline 615.3.7 Osteoarthritis Pain Market – Discovery and Pre-Clinical Pipeline 615.3.8 Technology Trends Analytic Framework 625.4 Osteoarthritis Pain Therapeutics Market –Pipeline by Mechanism of Action 64
5.5 Molecule Profile for Promising Drugs Under Development 655.5.1 2 PX 655.5.2 Civanex 665.5.3 BEMA 675.5.4 CEP-33237 675.6 Key Takeaway 676 Osteoarthritis Pain Therapeutics - Clinical Trials Mapping 686.1 Clinical Trials by Region/Country (the US, EU5 and Japan) 686.2 Clinical Trials by Phase 696.3 Clinical Trials by Trial Status 706.4 Prominent Sponsors 716.5 Top Companies Participating in OA Pain Therapeutics Clinical Trials 737 Strategic Assessment 747.1 Key Events Impacting the Future Market 747.2 Osteoarthritis Pain Therapeutics: Implications for Future Market Competition 758 Osteoarthritis Pain Therapeutics - Future Players 768.1 Introduction 768.2 Company Profiles 778.2.1 Winston Pharmaceuticals, Inc. 778.2.2 Teva Pharmaceuticals 778.2.3 Pfizer, Inc. 798.2.4 SantoSolvo AS 818.2.5 BioDelivery Sciences International, Inc. 828.2.6 Savient Pharmaceuticals, Inc. 838.2.7 Eli Lilly and Company 848.2.8 Horizon Pharma 858.2.9 Boehringer Ingelheim 859 Osteoarthritis Pain Therapeutics - Licensing and Partnership Deals 8710 Osteoarthritis Pain Therapeutics - Appendix 8810.1 Market Definitions 8810.2 Abbreviations 8810.3 Bibliography 8910.4 Methodology 9110.4.1 Coverage 9110.4.2 Secondary Research 9110.4.3 Forecasting 9210.4.4 Primary Research 9410.4.5 Expert Panel Validation 9510.5 Contact Us 9510.6 Disclaimer 95Related Reports @ http://www.reportsnreports.com/publisher/globaldata/
Contact:TX, Dallas North - Dominion Plaza,17304, Preston Road,Suite 800, Dallas 75252.Tel: + 1 888 391 email@example.comConnect With Us: